Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib + Rituximab vs R-CHOP in Relapsed/Refractory Follicular Lymphoma
NCT02605694Phase 2Withdrawn
- Sponsor
- Secura Bio
- Start
- Dec 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of duvelisib in follicular lymphoma (FL) (2 arms), sponsored by Secura Bio. Primary endpoint: Progression Free Survival at 44 months. Planned start Dec 2015; status: withdrawn.
02
Drugs
duvelisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02605694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605694.